A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia
Status:
Completed
Trial end date:
2017-10-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children
with achondroplasia. The primary objective is to assess the safety and tolerability of daily
BMN 111 administered to children with achondroplasia.